

Form PTO-1449

**SUPPLEMENTAL  
INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**  
(Use several sheets if necessary)

Docket Number (Optional)  
N/TV-051.01

Applicant  
Lippard, Stephen J., et al.

Filing Date  
January 12, 2004

Application Number  
10 755,855

Group Art Unit  
1614

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AGK	AA 5,547,982	08-20-96	Abrams, et al.	514	492	
	AB 4,271,085	06-02-81	Amundsen, et al.	556	1376	
	AC 4,457,926	07-03-84	Amundsen, et al.	514	184	
	AD 4,462,998	07-31-84	Amundsen, et al.	514	184	
	AE 4,505,928	03-19-85	Amundsen, et al.	514	492	
	AF 5,519,155	05-21-96	Barnard, et al.	556	137	
	AG 5,225,207	07-06-93	Barreau, et al.	424	649	
	AH 2004/0006051	01-08-04	Berube	514	169	
	AI 6,825,330	11-30-04	Braman, et al.	536	23.1	
	AJ 5,484,612	01-16-96	Brown	424	649	
	AK 5,194,644	03-16-93	Brunner, et al.			
	AL 5,238,955	08-24-93	Brunner, et al.			
	AM 6,313,333	11-06-01	Da Re, et al.	556	137	
	AN 4,937,262	06-26-90	Davidson	514	492	
	AO 4,659,849	04-21-87	Drobnik, et al.	556	137	
	AP 5,028,726	07-02-91	Farrell	556	137	
	AQ 5,409,915	04-25-95	Farrell, et al.	514	187	
	AR 5,624,919	04-29-97	Farrell	514	184	
	AS 5,770,591	06-23-98	Farrell	514	187	
	AT 6,022,892	02-08-00	Farrell, et al.	514	492	
	AU 6,060,616	05-09-00	Farrell, et al.	556	137	
	AV 6,113,934	09-05-00	Farrell, et al.	424	405	
	AW 4,760,155	07-26-88	Heffernan, et al.	556	136	
	AX 4,760,156	07-26-88	Heffernan, et al.	556	136	
	AY 4,952,676	08-28-90	Heffernan, et al.	530	391.5	
	AZ 4,956,454	09-11-90	Heffernan, et al.	424	179.1	
AGK	BA 4,577,018	03-18-86	Hlavka, et al.	544	225	

*Andrew O'Korn 11/16/05*

Form PTO-1449			Docket Number (Optional) MTV-061.01		Application Number 10 755,655		
<b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>			Applicant Lippard, Stephen J., et al.				
			Filing Date January 12, 2004		Group Art Unit 1614		
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
ADK	BB 4,234,500	11-18-80	Hoeschele, et al.	556	17		
	BC 4,291,027	09-22-81	Hoeschel, et al.	514	76		
	BD 5,380,897	01-10-95	Hoeschele, et al.	556	137		
	BE 5,714,327	02-03-98	Houthoff, et al.	435	6		
	BF 5,985,566	11-16-99	Houthoff, et al.	435	6		
	BG 6,133,038	10-17-00	Houthoff, et al.	436	84		
	BH 6,248,531	06-19-01	Houthoff, et al.	435	6		
	BI 5,256,653	10-26-93	Keppler, et al.	514	79		
	BJ 4,416,878	11-22-83	Klosa	514	186		
	BK 4,870,062	09-26-89	Kurono, et al.	514	63		
	BL 4,843,161	06-27-89	Lippard, et al.	546	10		
	BM 4,284,579	08-18-81	Meischen, et al.	556	19		
	BN 4,428,943	01-31-84	Meischen, et al.	514	119		
	BO 5,902,826	05-11-99	Mogi, et al.	514	492		
	BP 4,912,100	03-27-90	Ohno, et al.	514	184		
	BQ 4,980,347	12-25-90	Ohno, et al.	514	186		
	BR 4,732,893	03-22-88	Pasini, et al.	514	185		
	BS 5,198,564	03-30-93	Quianhuan	556	137		
	BT 6,605,734	08-12-03	Roy, et al.	556	9		
	BU 4,793,986	12-27-88	Serino, et al.	424	1.53		
	BV 6,130,245	10-10-00	Shaw	514	492		
	BW 4,921,963	05-01-90	Skov, et al.	548	101		
	BX 5,026,694	06-25-91	Skov, et al.	514	184		
	BY 6,333,422	12-25-01	Sohn, et al.	556	17		
ADK	BZ 5,104,895	04-14-92	Spinelli, et al.	514	492		

*Andrew O'Keefe* 11/16/05

Form PTO-1449 <b>SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>	Pocket Number (Optional) NTV-091.01	Application Number 10 755,855
	Applicant Lippard, Stephen J., et al.	
	Filing Date January 12, 2004	Group Art Unit 1614

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ADK	CA 6,692,734	02-17-04	Stewart, et al.	424	78.27	
	CB 4,590,001	05-20-86	Stjernholm	530	394	
	CC RE33,071	09-26-89	Stjernholm	530	394	
	CD 5,633,243	05-27-97	Sugimura, et al.	514	184	
	CE 4,560,781	12-24-85	Totani, et al.	556	137	
	CF 5,744,497	04-28-98	Valsecchi, et al.	514	492	
	CG 6,011,166	01-04-00	Valsecchi, et al.	556	137	
	CH 4,992,553	02-12-91	Von Angerer, et al.	546	12	
	CI 5,561,042	10-01-96	Weis, et al.	435	6	
ADK	CJ 5,498,780	03-12-96	Yokui, et al.	514	492	

### FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
						YES	NO
ADK	CK WO 03/017993	03-06-03	PCT				
	CL EP 1 262 778	04-12-02	EPO				
	CM WO 00/27847	05-18-00	PCT				
	CN WO 96/35696	11-14-96	PCT				
ADK	CO 0 169 645	01-29-06	EPO				

### OTHER DOCUMENTS

*(Including Author, Title, Date, Pertinent Pages Etc.)*

ADK	CP	ARAP, Wadih, et al., "Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model," Science, Vol. 279, 16 January 1998, pp. 377-380.
	CQ	BROWN, Steven J., et al., "1xrl, a Yeast Protein That Binds to Platinated DNA and Confers Sensitivity to Cisplatin," Science, Vol. 261, 30 July 1993, pp. 603 - 605.
	CR	CHEN, Lie, et al., "Reduction of the anti-cancer drug analogue <i>cis, trans, cis</i> -[PtCl <sub>2</sub> (OCOCH <sub>3</sub> ) <sub>2</sub> (NH <sub>3</sub> ) <sub>2</sub> ] by L-cysteine and L-methionine and its crystal structure," J. Chem. Soc., Dalton Trans., 1999, pp. 1209-1212.
	CS	COHEN, Seth M., et al., "Cisplatin: From DNA Damage to Cancer Chemotherapy," Progress in Nucleic Acid Research and Molecular Biology, Vol. 67, 2001, pp. 93-130.
ADK	CT	DHARA, S.C., "A Rapid Method for the Synthesis of <i>cis</i> -[Pt(NH <sub>3</sub> ) <sub>2</sub> Cl <sub>2</sub> ], Indian Journal of Chemistry, Vol. 8, No. 2, February 1970, pp. 193-194.

Andrew O Kom 11/16/05

Form PTO-1449	Supplemental INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number (Optional) MTV-C61.01	Application Number 10 755,855
		Applicant Lippard, Stephen J., et al.	
		Filing Date January 12, 2004	Group Art Unit 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

ADK	CU	ELLERBY, H. Michael, et al., "Anti-cancer activity of targeted pro-apoptotic peptides," <i>Nature Medicine</i> , Vol. 5, No. 9, September, 1999, pp. 1032-1038.
	CV	FOLKMAN, Judah, "What Is the Evidence That Tumors Are Angiogenesis Dependent?", <i>Journal of the National Cancer Institute</i> , Vol. 82, No. 1, January 3, 1990, pp. 4-6.
	CW	FOLKMAN, Judah, <i>Alternative Strategies for Biologic Therapy</i> , Chapter 30, Antiangiogenesis, pp. 743-753.
	CX	FOLKMAN, Judah, et al., "Minireview, Angiogenesis," <i>The Journal of Biological Chemistry</i> , Vol. 267, No. 16, Issue of June 5, 1992, pp. 1031-1034.
	CY	GIANDOMENICO, Christen M., et al., "Carboxylation of Kinetically Inert Platinum (IV) Hydroxy Complexes. An Entrée into Orally Active Platinum(IV) Antitumor Agents," <i>Inorganic Chemistry</i> , Vol. 34, No. 5, 1995, pp. 1015-1021.
	CZ	HAMBLEY, T.W., et al., "Modifying the Properties of Platinum (IV) Complexes in Order to Increase Biological Effectiveness," <i>Journal of Inorganic Biochemistry</i> , 77 (1999), pp. 3-12.
	DA	HAMMES, Hans-Peter, et al., "Subcutaneous Injection of a Cyclic Peptide Antagonist of Vitronectin Receptor-Type Integrins Inhibits Retinal Neovascularization," <i>Nature Medicine</i> , Vol. 2, No. 5, May 1996, pp. 529-533.
	DB	HART, Stephen L, et al., "Cell Binding and Internalization by Filamentous Phage Displaying a Cyclic Arg-Gly-Asp-containing Peptide," <i>The Journal of Biological Chemistry</i> , Vol. 269, No. 17, Issue of April 29, 1994, pp. 12468-12474.
	DC	HEALY, Judith M., et al., "Peptide Ligands for Integrin $\alpha_5\beta_1$ Selected from Random Phage Display Libraries," <i>Biochemistry</i> , Vol. 34, No. 12, 1995, pp. 3948-3955.
	DD	HOUSTON, Parul, et al., "Homing markers for atherosclerosis: applications for drug delivery, gene delivery and vascular imaging," <i>Federation of European Biochemical Societies</i> , 2001, pp. 73-77.
	DE	HUANG, Juch-Chin, et al., "HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease," <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 91, October 1994, pp. 10394-10398.
	DF	JAMIESON, Elizabeth R., et al., "Structure, Recognition, and Processing of Cisplatin-DNA Adducts," <i>Chemical Reviews</i> , 1999, pp. 2467-2498.
	DG	KARTALOU, Maria, et al., "Recognition of cisplatin adducts by cellular proteins," <i>Mutation Research</i> 478 (2001), pp. 1-21.
	DH	KOIVUNEN, Erkki, et al., "Isolation of a Highly Specific Ligand for the $\alpha_5\beta_1$ Integrin from a Phage Display Library," <i>The Journal of Cell Biology</i> , Vol. 124, No. 5, February 1994, pp. 373-380.
	DI	KOIVUNEN, Erkki, et al., "Selection of Peptides Binding to the $\alpha_5\beta_1$ Integrin from Phage Display Library," <i>The Journal of Biological Chemistry</i> , Vol. 268, No. 27, Issue of September 25, 1993, pp. 20205-20210.
	DJ	KOIVUNEN, Erkki, et al., "Phage Libraries Displaying Cyclic Peptides with Different Ring Sizes: Ligand Specificities of the RGD-Directed Integrins," <i>Bio/Technology</i> , Vol. 13, March 1995, pp. 265-270.
ADK	DK	LEE, Keng-Boon, et al., "Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase II in vitro," <i>PNAS</i> , Vol. 99, No. 7, April 2, 2002, pp. 4239-4244.



Form PTO-1449	Docket Number (Optional) MTV-061.01	Application Number 10/755,855
SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Lippard, Stephen J., et al.
Filing Date January 12, 2004		Group Art Unit 1614

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages Etc.)

ADK	DL	LEE, Young-A, et al., "Synthesis and Oral Antitumor Activity of Tetrakis (carboxylato) platinum (IV) Complexes," <i>J. Med. Chem.</i> , Vol. 43, No. 7, 2000, pp. 1409-1412.
	DM	LEMMA, Kelemu, et al., "Kinetics and Mechanism for Reduction of the Anticancer Prodrug trans,trans,trans-[PtCl <sub>2</sub> (OH) <sub>2</sub> ](c-C <sub>6</sub> H <sub>11</sub> NH <sub>2</sub> )(NH <sub>3</sub> )] (JM335) by Thiols," <i>Inorganic Chemistry</i> , Vol. 39, No. 8, 2000, pp. 1728-1734.
	DN	LEMMA, Kelemu, et al., "Kinetics and Mechanism for reduction of anticancer-active tetrachloroam(m)ine platinum(IV) compounds by glutathione," <i>Journal of Biological Inorganic Chemistry</i> , Vol. 5, No. 3, June, 2000, pp. 300-306.
	DO	LEMMA, Kelemu, et al., "Kinetics and mechanism for reduction of halo-and haloam(m)ine platinum(IV) complexes by L-ascorbate," <i>Inorganica Chimica Acta</i> , 331, 2002, pp. 98-108.
	DP	MACLUSKY, NEIL J., et al., "Actions of an Estradiol-17-Fatty Acid Ester in Estrogen Target Tissues of the Rat: Comparison with Other C-17 Metabolites and a Pharmacological C-17 Ester," <i>Endocrinology</i> , Vol. 124, No. 1, 1989, pp. 318-324.
	DQ	ORME, Mark W., et al., "Synthesis of $\beta$ -Estradiol-3-Benzoyl-17-(Succinyl-12A-Tetracycline): A Potential Bone-Seeking Estrogen," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , Vol. 4, No. 11, 1994, pp. 1375-1380.
	DR	PASQUALINI, Renata, et al., "Organ targeting in vivo using phage display peptide libraries," <i>Nature</i> , Vol. 380, 28 March 1996, pp. 364-366.
	DS	QING, He, et al., "Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin," <i>PNAS</i> , Vol. 97, No. 11, May 23, 2000, pp. 5768-5772.
	DT	RAJOTTE, Daniel, et al., "Molecular Heterogeneity of the Vascular Endothelium Revealed by In Vivo Phage Display," <i>J. Clin. Invest.</i> , Vol. 102, No. 2, July 1998, pp. 430-437.
	DU	REEDIJK, Jan, "The mechanism of action of platinum anti-tumor drugs," <i>Pure &amp; Appl. Chem.</i> , Vol. 59, No. 2, 1987, pp. 181-192.
	DV	ROSENBERG, Barnett, et al., "Inhibition of Cell Division in <i>Escherichia coli</i> by Electrolysis Products from a Platinum Electrode," <i>Nature</i> , Vol. 205, February 13, 1965, pp. 698-698.
	DW	RUOSLAHTI, Erkki, "Specialization of Tumour Vasculature," <i>Nature Reviews</i> , Vol. 2, February, 2002, pp. 83-90.
	DX	SHI, Tiesheng, et al., "Reduction of trans-dichloro- and trans-dibromo-tetracyano-platinate (IV) by L-methionine," <i>J. Chem. Soc., Dalton Trans.</i> , 1997, pp. 2073-2077.
	DY	SHI, Tiesheng, et al., "Kinetics and Mechanism for Reduction of trans-Dichlorotetracyanoplatinate(IV) by "Thioglycolic Acid, L-Cysteine, DL-Penicillamine, and Glutathione in Aqueous Solution," <i>Inorganic Chemistry</i> , Vol. 35, No. 12, 1996, pp. 3498-3503.
	DZ	TAKAHARA, Patricia M., et al., "Crystal Structure of the Anticancer Drug Cisplatin Bound to Duplex DNA," <i>J. Am. Chem. Soc.</i> , Vol. 118, No. 49, 1996, pp. 12309-12321.
	EA	TREIBER, Daniel K., et al., "Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor), <i>Proc. Natl. Acad. Sci.</i> , Vol. 91, June 1994, pp. 5672-5676.
ADK	EB	TREPEL, M., et al., "Exploring vascular heterogeneity for gene therapy targeting," <i>Gene Therapy</i> , 2000.

Andrew O'Hara 11/6/05

Form PTO-1449 <b>SUPPLEMENTAL          INFORMATION DISCLOSURE CITATION          IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i>	Docket Number (Optional) MTV-061.01	Application Number 10 755,855
	Applicant Lippard, Stephen J., et al.	
	Filing Date January 12, 2004	Group Art Unit 1614

**OTHER DOCUMENTS***(Including Author, Title, Date, Pertinent Pages Etc.)*

ADL	EC TRIMMER, Elizabeth E., et al., "Cisplatin," Essays in Biochemistry, Vol. 34, 1999, pp. 191-211.
	ED WONG, Ernest, et al., "Current Status of Platinum-Based Antitumor Drugs," Chem. Rev. Vol. 99, No. 9, 1999, pp. 2451-2466.
ADL	EE ZIEGLER, Christopher J., et al., "High-throughput synthesis and screening of platinum drug candidates," J. Biol. Inorg. Chem., 2000, pp. 774-783.
EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant. <i>Andrew O'Korn 11/16/05</i>	

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE